AdAlta Ltd.ASX: 1AD

SYNBV invest up to $2m in East to West subsidiary

· Issued by AdAlta Ltd.

Filed with ASX · · 5 pages · English

Summary by 6ix AI

This investment will support planning and preparation for clinical development of three cellular immunotherapy assets being considered for licensing by AdCella. Completion of the transaction is expected before mid-April and is subject to final agreements and regulatory compliance.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

AdAlta Ltd. on 6ix

Earlier from AdAlta

Later from AdAlta

All AdAlta news releases